Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosingThe Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALSA Type B end-o...
Epsilon Announces Second Quarter 2025 Results and Transformative Acquisitions in the Powder River Basin HOUSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced it has entered into definitive agreements to acquire two entities (Peak Exploration and Production LLC and Peak BLM Lease LLC, together “Peak”) majority owned by funds of Yorktown Energy Partners LLC. Combined consideration due at closing is the issuance of 6 million Epsilon common shares and the assumption of an estimated $49 million of debt...
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 20, 2025Time of Presentation: 2:20 p.m. ETFormat: Corporate ...
Clene to Present at the Canaccord 45th Annual Growth Conference SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings. Date: August 12th, 2025Time of Presen...
Epsilon Energy Ltd. Schedules Second Quarter 2025 Earnings Release and Conference Call HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its second quarter 2025 earnings release on Wednesday, August 13, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, August 14, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. Inte...
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3rd Quarter of 2025, to discuss ALS survival data and MS clinical development programSubmission of new drug application for ALS under the accelerated a...
Epsilon Energy Ltd. Announces Quarterly Dividend HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the stock holders of record at the close of business on June 13, 2025, payable on June 30, 2025. All dividends paid by the Company are “eligible dividends” as defined in subsection 89(1) of the Income Tax Act (Canada), unless indicated otherwise. About Epsilon Epsilon Energy Ltd. is a North American on...
Epsilon Announces 2025 AGM Results HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) is pleased to announce that all the nominees listed in its Proxy Statement, Schedule 14A dated on April 17, 2025 were elected as directors of Epsilon, until the next annual meeting of shareholders. The detailed results of the vote at the annual shareholders meeting held on Wednesday, May 21, 2025 are set out below. At the meeting, the number of directors was set at six and each of the following six nominees proposed by management was elected as a d...
Epsilon Reports First Quarter 2025 Results HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported first quarter 2025 financial and operating results. First Quarter 2025 Highlights: Epsilon - Q1 2025 Q1 2025Q4 2024Q1 2024QoQ%YoY%NRI Production GasMMcf2,7401,7651,66655%64%OilMbbl465237-12%24%NGLMbbl161716-6%-2%TotalMmcfe3,1082,1761,98243%57% Revenues$M Gas 10,6143,9582,963168%258%Oil 3,2703,5372,715-8%20%NGL 3873853731%4%Midstream1 1,8921,0601,93679%-2%Total 16,1638,9407,98781%102% Realized Pric...
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and ne...
Epsilon Energy Ltd. Schedules First Quarter 2025 Earnings Release and Conference Call HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its first quarter 2025 earnings release on Wednesday, May 14, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, May 15, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International p...
A director at FB Financial Corp bought 7,200 shares at 40.490USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:00 p.m. EDTFormat: Corporate updat...
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Clene, Inc...
Clene to Present at the Jones Healthcare and Technology Innovation Conference SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings. Date: Apr...
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025Secured new $10.0 million debt facility at a lower interest rate to replace remaining outstanding $7.85 million debt balance with Avenue Capital Cash, cash equivalents and marketable securities of $12.2 million as of December 31, 2024, includes $7.3 million in gross proceeds raised...
Epsilon Announces Full Year 2024 Results HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year and Q4 2024 Highlights: Epsilon - Full Year 2024 & Q4 2024 20242023Q4 2024Q3 2024YoY%QoQ%NRI Production GasMMcf6,1428,3401,7651,304-26%35%OilMbbl187655253186%-3%NGLMbbl6939171778%-2%TotalMmcfe7,6768,9652,1761,727-14%26% Revenues$M Gas 10,78614,8643,9581,904-27%10...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.